Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928731 | 0.83 | MEN1 (0.37) | HPGDHSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL9928958 | 0.81 | MEN1 (0.36) | HPGDHSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL6336249 | 0.79 | TPMT (0.42) | HPGDHSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL15283183 | 0.78 | TTR (0.39) | MEN1KMT2AKDM4EMAPTNSD2 | |
| SCHEMBL9928852 | 0.77 | ABCB11 (0.37) | HPGDHSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL22991360 | 0.74 | MEN1 (0.50) | HPGDMEN1KMT2AKDM4EMAPT | |
| SCHEMBL22991359 | 0.74 | TTR (0.42) | MEN1KMT2AKDM4EMAPTNSD2 | |
| SCHEMBL14885189 | 0.74 | AKR1C2 (0.41) | HPGDHSD17B10TSHRCASP1MEN1 | |
| SCHEMBL10498598 | 0.73 | CYP3A4 (0.46) | HPGDHSD17B10TSHRCASP1MEN1 | |
| SCHEMBL14753933 | 0.72 | MEN1 (0.40) | HPGDHSD17B10MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | INCYTE CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4233869-A2 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| EP-3632442-B1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | INCYTE HOLDINGS CORP (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2012135009-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HPGD 678/4885HSD17B10 2074/4885TSHR 3486/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HPGD 678/4885HSD17B10 2074/4885TSHR 3486/4885 |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | HPGD 2502/4885HSD17B10 4521/4885TSHR 3968/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HPGD 678/4885HSD17B10 2074/4885TSHR 3486/4885 |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | PIK3CD, PIK3CA, PIK3R5 | HPGD 1252/4885HSD17B10 946/4885TSHR 2873/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | HPGD 678/4885HSD17B10 2074/4885TSHR 3486/4885 |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | HPGD 1177/4885HSD17B10 1032/4885TSHR 3230/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | HPGD 678/4885HSD17B10 2074/4885TSHR 3486/4885 |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HPGD 1260/4885HSD17B10 3051/4885TSHR 3688/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HPGD 678/4885HSD17B10 2074/4885TSHR 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.